Market Cap | 131.40M | P/E | - | EPS this Y | -31.70% | Ern Qtrly Grth | - |
Income | -25.8M | Forward P/E | -2.98 | EPS next Y | -32.90% | 50D Avg Chg | - |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 0.84 | EPS next 5Y | - | 52W High Chg | -42.00% |
Recommedations | 1.60 | Quick Ratio | 40.30 | Shares Outstanding | 44.24M | 52W Low Chg | 113.00% |
Insider Own | 2.28% | ROA | -12.87% | Shares Float | 24.61M | Beta | 1.69 |
Inst Own | 78.64% | ROE | -17.05% | Shares Shorted/Prior | 769.26K/0.93M | Price | 2.98 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 38,924 | Target Price | 19.00 |
Oper. Margin | - | Earnings Date | May 7 | Volume | 49,509 | Change | -0.67% |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Oppenheimer | Outperform | Dec 13, 23 |
Oppenheimer | Outperform | Aug 9, 23 |
Piper Sandler | Overweight | May 12, 22 |
Oppenheimer | Outperform | Aug 17, 21 |
Piper Sandler | Overweight | Mar 4, 21 |
HC Wainwright & Co. | Buy | Feb 25, 21 |
HC Wainwright & Co. | Buy | Feb 11, 21 |
HC Wainwright & Co. | Buy | Jan 11, 21 |
Oppenheimer | Outperform | Oct 25, 19 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Virsik Peter | Chief Operating Offi.. Chief Operating Officer | Feb 05 | Sell | 9.65 | 1,194 | 11,522 | 13,328 | 02/06/24 |
Virsik Peter | Chief Operating Offi.. Chief Operating Officer | Feb 05 | Option | 3.23 | 500 | 1,615 | 13,828 | 02/06/24 |
Virsik Peter | Chief Operating Offi.. Chief Operating Officer | Jan 16 | Sell | 10.01 | 1,718 | 17,197 | 14,022 | 01/17/24 |
Virsik Peter | Chief Operating Offi.. Chief Operating Officer | Jan 16 | Option | 3.23 | 1,718 | 5,549 | 15,740 | 01/17/24 |
Virsik Peter | Chief Operating Offi.. Chief Operating Officer | Jan 05 | Sell | 6.11 | 699 | 4,271 | 14,022 | 01/08/24 |
Parkinson David Ross | Chief Executive Offi.. Chief Executive Officer | Dec 14 | Buy | 2.30 | 9,223 | 21,213 | 65,675 | 12/18/23 |
BERGER FRANKLIN M | Director Director | Nov 21 | Buy | 5.73 | 23,259 | 133,274 | 784,404 | 11/22/23 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Jul 18 | Buy | 3.1558 | 300,000 | 946,740 | 5,879,583 | 07/20/22 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Jul 14 | Buy | 2.96 | 588,869 | 1,743,052 | 5,579,583 | 07/18/22 |
Parkinson David Ross | Chief Executive Offi.. Chief Executive Officer | Jun 30 | Buy | 2.958 | 4,887 | 14,456 | 32,108 | 07/05/22 |
BIOTECH GROWTH N V | 10% Owner 10% Owner | Apr 27 | Sell | 5.8536 | 25,100 | 146,925 | 4,990,714 | 04/28/22 |